$1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction.
Investors were led by Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). Additional investors included ARK Investment Management LLC, ArrowMark Partners, Bain Capital Public Equity, Cascade Investment, Casdin Capital, Franklin Advisers, T. Rowe Price, and Viking Global Investors.
Business combination with Ginkgo approved by Soaring Eagle shareholders with 75% of shareholders participating in the vote and 97% voting in favor of the transaction.
Soaring Eagle Acquisition Corp. (the “Company” or “Soaring Eagle”) (Nasdaq: SRNGU, SRNG, SRNGW) announced today that its business combination (the “Business Combination”) with Ginkgo Bioworks, Inc. (“Ginkgo”) was overwhelmingly approved in a shareholder vote held this morning, with 75% of shareholders participating in the vote and 97% voting in favor of the combination. Upon the closing of the Business Combination (the “Closing”), Ginkgo Bioworks expects to receive $1.633 billion of gross proceeds, including $775 million in committed funding from a PIPE plus approximately $858 million from the Soaring Eagle trust account.
Subject to the satisfaction or waiver of the other customary closing conditions, Soaring Eagle anticipates completing its domestication to Delaware on September 15, 2021 and closing the Business Combination on September 16, 2021. In connection with the Closing, the Company will change its name to Ginkgo Bioworks Holdings, Inc. and the combined company’s shares of Class A common stock and public warrants are expected to trade on the New York Stock Exchange beginning on September 17, 2021 under the ticker symbols “DNA” and “DNA.WS,” respectively.
Ginkgo Bioworks is building the world’s leading horizontal platform for cell programming. Companies across numerous industries use Ginkgo's platform to find more effective, environmentally friendly ways to create products including food ingredients, fragrances, cosmetics, medicines, and more. By enabling the design of organisms that can produce valuable biological products, Ginkgo helps accelerate the development of innovative, bio-based solutions to the world's most pressing challenges.
Ginkgo recently announced breakthrough improvements in production of a key material used in mRNA vaccine manufacturing with partner Aldevron, and commercial scale production of the rare cannabinoid CBG with partner Cronos Group. In addition to its cell programming work, Ginkgo last year launched Concentric by Ginkgo, the company’s public health and biosecurity initiative, to provide a response to the COVID-19 pandemic. Since then, Concentric has built a turnkey solution which is being used by states, cities, and school districts to enable universal testing in K-12 schools across the country.
“Ginkgo Bioworks sits at the intersection of technology and life sciences and has built a platform for cell programming that will transform the way products are made across markets,” said Harry Sloan, Chairman and CEO of Soaring Eagle. “It has been a privilege to get to know the team at Ginkgo and we are proud to support this next leg of their journey as a public company, where they will be capitalized to quickly make an impact in this field.”
“Ginkgo seeks to make programming the DNA of cells as easy as programming computers. Our platform benefits from scale and the proceeds from this transaction will help Ginkgo expand our platform to better serve our customers and become the industry standard across all biotechnology end-markets,” said Jason Kelly, CEO and co-founder of Ginkgo. “The partnership between the Soaring Eagle team and Dr. Arie Belldegrun has combined world-class capital markets and therapeutics experience and we look forward to welcoming both Harry and Arie onto the board.”
About Soaring Eagle Acquisition Corp.
Soaring Eagle Acquisition Corp. is a special purpose acquisition company founded by Harry E. Sloan, Jeff Sagansky, and Eli Baker for the purpose of effecting a merger, capital share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Seth Yakatan
Known for solutions that yield results, Seth Yakatan has completed or advised on acquisitions and corporate finance transactions totaling over $3 billion. He is CEO of Katan Associates International—a financial strategy and merchant banking firm specializing in commercialization and asset monetization—especially those within life-science and e-commerce sectors.
Source:
https://www.businesswire.com/news/home/20210914005748/en/Ginkgo-Bioworks-to-Go-Public-with-Over-1.6-Billion-in-Proceeds